KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查 入排置信度 0.98

MG-K10, a Long-Acting Anti-IL-4 Receptor Alpha Monoclonal Antibody in Adult Patients with Moderate-to-Severe Atopic Dermatitis.

Chaoying Gu, Litao Zhang, Yumei Li, Yunsheng Liang, Xiaoyan Chen, Yangfeng Ding, Yuling Shi, Jingyi Li, Ai'e Xu, Jinyan Wang, Kun Chen, Liming Wu, Xiaohua Tao, Fang Xie, Shifa Zhang, Linfeng Li, Danqi Deng, Jianyun Lu, Chao Ji, Jianhua Wu, Lunfei Liu, Sen Yang, Qing Guo, Yi Zhao, Rupeng Wang, Chenghai Zhang, Lingqiao Zhu, Di Qin, Jinhua Xu

Dermatitis 37(2) 253-263

PMID41189512
PMCID-
DOI10.1177/17103568251388478
发表日期2025-11-05
入排依据:未发现恶性肿瘤人群证据。
入排复审未纳入:未发现恶性肿瘤人群证据。
摘要

摘要

Background: There remains unmet need for therapies for atopic dermatitis (AD) with favorable symptom control but less frequent dosing.Objective: To evaluate the benefits and safety of MG-K10, a humanized interleukin-4 receptor alpha-targeting antibody, in moderate-to-severe AD.Methods: In this multi-center, double-blind, randomized, phase II trial, 163 moderate-to-severe AD patients were randomized to receive 16-week treatment with MG-K10 150 mg every 4 weeks (Q4W), 300 mg every 2 weeks (Q2W) (n = 41), 300 mg Q4W (n = 41), or placebo (n = 40). Primary endpoint was the change in Eczema Area and Severity Index (EASI) scores from baseline to week 16.Results: The mean differences in EASI score at week 16 for the 300 mg Q4W, 300 mg Q2W, and 150 mg Q4W groups were -38.83% (95% confidence interval [CI]: -56.47% to -21.20%, P < 0.001), -27.06% (95% CI: -44.73% to -9.38%, P = 0.003), and -16.00% (95% CI: -33.66% to 1.67%, P = 0.076) compared with placebo group. The proportion of participants achieving EASI-75 at week 16 was 79.5%, 66.7%, 53.8%, and 28.9% in the 300 mg Q4W, 300 mg Q2W, 150 mg Q4W, and placebo groups. The incidence of adverse events was comparable across groups.Conclusion: MG-K10 demonstrates potential as a long-acting therapeutic option for managing symptoms of moderate-to-severe AD, with favorable safety profile. The preliminary efficacy and safety supported further validation of 300 mg Q4W in phase III trial.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。